Sami Labs Ltd
Sami Labs Ltd
Majeed M.,Sami Labs. Ltd |
Bani S.,Sami Labs. Ltd |
Natarajan S.,Sami Labs. Ltd |
Pandey A.,Sami Labs. Ltd |
S N.,ClinWorld Private Ltd
PLoS ONE | Year: 2017
3′-Hydroxypterostilbene (3′-HPT) is one of the active constituents of Sphaerophysa salsula and Pterocarpus marsupium. Despite many proposed therapeutic applications, the safety profile of 3′-HPT has not been established. The present work investigated 90 day repeated oral dose and reproductive (developmental) toxicity of 3′-HPT as a test substance in rats as per OECD guidelines. 90 day toxicity was conducted in sixty Sprague Dawley rats of each sex (120 rats), grouped into six dosage groups of 0 (control), 0 (control recovery), 20 (low dose), 80 (mid dose), 200 (high dose) and 200 (high dose recovery) mg/kg bwt/day (body weight/day) respectively. For the reproductive toxicity study forty Wistar rats of each sex (80 rats) divided into four dosage groups received 0 (vehicle control), 20 (low dose), 100 (mid dose) and 200 (high dose) mg/kg bwt/day of 3′-HPT respectively for a period of two weeks while pre-mating, mating, on the day before sacrifice, in females during pregnancy and four days of lactation period. Results showed no significant differences in body weight, food intake, absolute organ weight, haematology, with no adverse effects (toxicity) on biochemical values nor any abnormal clinical signs or behavioural changes were observed in any of the control/treatment groups, including reproductive and developmental parameters, gross and histopathological changes. In conclusion, the results suggested a No-Observed-Adverse-Effect-Level (NOAEL) of 200 mg/kg bwt/day in rats after oral administration, implying 3′-HPT did not exhibit any toxicity under the study conditions employed. © 2017 Majeed et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
News Article | April 26, 2017
— Global Ursolic Acid Industry Report offers market overview, segmentation by types, application, countries, key manufactures, cost analysis, industrial chain, sourcing strategy, downstream buyers, marketing strategy analysis, distributors/traders, factors affecting market, forecast and other important information for key insight. Companies profiled in this report are Sabinsa, Sami Labs, Changsha Staherb Natural Ingredients, Run Shaanxi Days Of Bio-Tech, Shaanxi Huike Botanical Development, Changsha Luyuan Bio-Tech, Xuancheng Baicao Pharmaceutical, Changsha E.K Herb, Shaanxi Jintai Biological Engineering, Hunan Nutramax, Xi’an Tonking, Zhangjiajie Hengxing Biological Technology, Microherb, Geneham Pharmaceutical, Acetar Bio-Tech, Shaanxi Hopeland Chem-Tech, Xi'an Tianben Bio-Engineering, Aikang Biological in terms of Basic Information, Manufacturing Base, Sales Area and Its Competitors, Sales, Revenue, Price and Gross Margin (2012-2017). Split by Product Types, with sales, revenue, price, market share of each type, can be divided into • 25% Ursolic Acid • 50% Ursolic Acid • 90% Ursolic Acid • 98% Ursolic Acid • Others Split by applications, this report focuses on sales, market share and growth rate of Ursolic Acid in each application, can be divided into • Pharmaceutical Industry • Cosmetic Industry • Food＆Health Care Products Industry Purchase a copy of this report at: https://www.themarketreports.com/report/buy-now/424288 Table of Content: 1 Ursolic Acid Market Overview 2 Global Ursolic Acid Sales, Revenue (Value) and Market Share by Manufacturers 3 Global Ursolic Acid Sales, Revenue (Value) by Countries, Type and Application (2012-2017) 4 Global Ursolic Acid Manufacturers Profiles/Analysis 5 North America Ursolic Acid Sales, Revenue (Value) by Countries, Type and Application (2012-2017) 6 Latin America Ursolic Acid Sales, Revenue (Value) by Countries, Type and Application (2012-2017) 7 Europe Ursolic Acid Sales, Revenue (Value) by Countries, Type and Application (2012-2017) 8 Asia-Pacific Ursolic Acid Sales, Revenue (Value) by Countries, Type and Application (2012-2017) 9 Middle East and Africa Ursolic Acid Sales, Revenue (Value) by Countries, Type and Application (2012-2017) 10 Ursolic Acid Manufacturing Cost Analysis 11 Industrial Chain, Sourcing Strategy and Downstream Buyers 12 Marketing Strategy Analysis, Distributors/Traders 13 Market Effect Factors Analysis 14 Global Ursolic Acid Market Forecast (2017-2022) 15 Research Findings and Conclusion 16 Appendix Inquire more for more details about this report at: https://www.themarketreports.com/report/ask-your-query/424288 For more information, please visit https://www.themarketreports.com/report/2017-2022-global-top-countries-ursolic-acid-market-report
Yadav V.,Banaras Hindu University |
Chatterjee S.S.,Stettiner Strae 1 |
Majeed M.,Sami Labs Ltd |
Kumar V.,Banaras Hindu University
Journal of Traditional and Complementary Medicine | Year: 2015
Aim: To compare stress resistance increasing and analgesic activities of piperlongumine and a methanolic Piper longum fruit extract (PLE). Methods: Efficacies of a single and repeated daily oral doses (1-256 mg/kg/day) of PLE, piperlongumine, and 50 mg/kg/day doxycycline against foot shock stress triggered alteration in body weights and core temperatures, and of their 11 daily doses on antidepressants like activity in tail suspension test and on pentobarbital induced sedation in male mice were compared. In another experiment, analgesic activities of single and repeated daily 5 mg/kg oral doses of piperlongumine and PLE in mice hot plate test and in acetic acid induced writing tests were compared with those of aspirin and doxycycline. Results: After their single oral doses no effects of piperlongumine or PLE or doxycycline were observed in the footshock stress induced hyperthermia test or in hot plate test. However, significant effects of piperlongumine and PLE in both the tests were observed after their 5 or more daily doses. Both of them also dose dependently suppressed daily handling and repetitive testing triggered alterations in body weights and core temperatures. Their doxycycline like antidepressant activity in tail suspension test and aspirin like analgesic effects in acetic acid writhing test were observed after their 11 daily 5 mg/kg oral dose. Conclusion: Piperlongumine is another bioactive secondary metabolite of P. longum and other plants of piper species with stress response suppressing, analgesic, and anti-inflammatory activities. Its bactericidal activities can also contribute to its therapeutically interesting bio-activity profile. © 2015 Center for Food and Biomolecules, National Taiwan University.
Ramanujam R.,Sami Labs Ltd |
Ganjihal S.,Sami Labs Ltd |
Kalyanam N.,Sabinsa Corporation |
Majeed M.,Sabinsa Corporation
Tetrahedron Asymmetry | Year: 2013
The synthesis of chemically and enantiomerically pure (S)-3-amino tetrahydrofuran hydrochloride starting from the natural amino acids, l-aspartic acid or l-methionine is described. The process involves no chromatography and can be easily carried out on a large scale. The enantiopurity of the final product was established by NMR and chiral HPLC methods. © 2013 Elsevier Ltd. All rights reserved.
Sami Labs Ltd | Date: 2012-10-17
The present invention relates to a composition containing peptide of SEQ ID No. 1 linked to oleanolic acid and a method of treating skin aging. The composition effectively reduces signs of ageing due to oxidation, collagen insufficiency and excess activity of serine proteases like elastase and collagenase that result in wrinkling of skin, fine expression lines, reduced skin thickness, hyperpigmentation, under eye dark circles, and premature ageing.
PubMed | National Taiwan University of Science and Technology, Sami Labs Ltd, Sabinsa Corporation, Rutgers University and National Kaohsiung Marine University
Type: Journal Article | Journal: Molecular nutrition & food research | Year: 2015
Diet-induced obesity and associated nonalcoholic fatty liver disease have increased and become a major health problem worldwide. This study was conducted to investigate the chemopreventive effects of dietary Calebin-A, a curcuminoid, on differentiation of 3T3-L1 adipocytes and high-fat diet (HFD) induced obesity and hepatic steatosis. Potential mechanisms contributing to these effects were also elucidated.Calebin-A effectively and dose dependently suppressed accumulation of lipid droplets in adipocytes through the suppression of adipogenic specific factor peroxisome proliferator-activated receptor (PPAR) and fatty acid synthase and activated acetyl-CoA carboxylase. Dietary Calebin-A effectively decreased weight gain and relative perigonadal, retroperitoneal, and mesenteric fat weight in HFD-fed mice. Furthermore, Calebin-A markedly reduced hepatic steatosis and the serum levels of glutamate oxaloacetate transaminase, glutamate pyruvate transaminase, total cholesterol, and triacylglycerol. These effects were associated with the downregulation of PPAR, sterol regulatory element-binding protein-1, and particularly the activation of AMP-activated protein kinase signaling found in both adipocytes and liver tissues.Taken together, these results demonstrated for the first time that Calebin-A suppressed adipocyte differentiation, prevented HFD-induced obesity, and improved hepatic steatosis, suggesting a novel application for the prevention and treatment of obesity and associated nonalcoholic fatty liver disease.
PubMed | Banaras Hindu University, Dr. Willmar Schwabe GmbH & Co. KG and Sami Labs Ltd
Type: Journal Article | Journal: Journal of intercultural ethnopharmacology | Year: 2015
To compare doxycycline (DOX) such as oral efficacies of piperlongumine (PL) and a Piper longum fruits extract (PLE) as stress resistance inducers.Efficacies of oral pretreatments with 5 mg/kg PL or PLE or of 50 mg/kg DOX for 10 consecutive days against stress resistance were compared. Mice in treated groups were subjected to a stress induced hyperthermia on the 1(st), 5(th), 7(th), and 10(th)day. Treated mice were then subjected to tail suspension test on the 11(th)day. Alteration in body weights, core temperatures, and gastric ulcers triggered by occasional exposures to foot shocks were determined.DOX like long-lasting protective effects of PL and PLE against gradual alterations in body weights, basal temperatures and transient hyperthermic responses triggered by foot shocks during the post-treatment days were observed. Altered responses of stressed mice in tail suspension test observed 1 day after the last foot-shock exposures and gastric ulcers and other pathologies quantified 1 day after the test were also suppressed in PL or PLE or DOX pretreated groups.PL and crude PLE are DOX like long-acting desensitizers of stress triggered co-morbidities. Reported observations add further experimental evidences justifying traditionally known medicinal uses of P. longum and other plants of the Piperaceae family, and reveal that PL is also another very long acting and orally active inducer of stress resistance. Efforts to confirm stress preventive potentials of low dose plant-derived products enriched in PL or piperine like amide alkaloids in volunteers and patients can be warranted.
PubMed | Sabinsa Corporation, FrieslandCampina Research and Sami Labs Ltd
Type: Journal Article | Journal: World journal of microbiology & biotechnology | Year: 2016
Commercial probiotics preparation containing Bacillus coagulans have been sold in the market for several decades. Due to its high intra-species genomic diversity, it is very likely that B. coagulans strain may alter in different ways over multiple years of production. Therefore, the present study focuses to evaluate the genetic consistency and probiotic potential of B. coagulans MTCC 5856. Phenotypic and genotypic techniques including biochemical profiling, 16S rRNA sequencing, GTG 5, BOX PCR fingerprinting, and Multi-Locus-Sequence typing (MLST) were carried out to evaluate the identity and consistency of the B. coagulans MTCC 5856. Further, in vitro probiotic potential, safety and stability at ambient temperature conditions of B. coagulans MTCC 5856 were evaluated. All the samples were identified as B. coagulans by biochemical profiling and 16S rRNA sequencing. GTG 5, BOX PCR fingerprints and MLST studies revealed that the same strain was present over 3years of commercial production. B. coagulans MTCC 5856 showed resistance to gastric acid, bile salt and exhibited antimicrobial activity in in-vitro studies. Additionally, B. coagulans MTCC 5856 was found to be non-mutagenic, non-cytotoxic, negative for enterotoxin genes and stable at ambient temperature (252C) for 36months. The data of the study verified that the same strain of B. coagulans MTCC 5856 was present in commercial preparation over multiple years of production.
PubMed | Sabinsa Corporation, ClinWorld Private Ltd and 19 1 & 19 2 and Sami Labs Ltd
Type: | Journal: Nutrition journal | Year: 2016
Bacillus coagulans MTCC 5856 has been marketed as a dietary ingredient, but its efficacy in diarrhea predominant irritable bowel syndrome (IBS) condition has not been clinically elucidated till date. Thus, a double blind placebo controlled multi-centered trial was planned to evaluate the safety and efficacy of B. coagulans MTCC 5856 in diarrhea predominant IBS patients.Thirty six newly diagnosed diarrhea predominant IBS patients were enrolled in three clinical centres. Along with standard care of treatment, 18 patients in group one received placebo while in group two 18 patients received B. coagulans MTCC 5856 tablet containing 2 10(9) cfu/day as active for 90 days. Clinical symptoms of IBS were considered as primary end point measures and were evaluated through questionnaires. The visual analog scale (VAS) was used for abdominal pain. Physicians global assessment and IBS quality of life were considered as secondary efficacy measures and were monitored through questionnaires.Laboratory parameters, anthropometric and vital signs were within the normal clinical range during the 90 days of supplementation in placebo and B. coagulans MTCC 5856 group. There was a significant decrease in the clinical symptoms like bloating, vomiting, diarrhea, abdominal pain and stool frequency in a patient group receiving B. coagulans MTCC 5856 when compared to placebo group (p < 0.01). Similarly, disease severity also decreased and the quality of life increased in the patient group receiving B. coagulans MTCC 5856 when compared to placebo group.The study concluded that the B. coagulans MTCC 5856 at a dose of 2 10(9) cfu/day along with standard care of treatment was found to be safe and effective in diarrhea predominant IBS patients for 90 days of supplementation. Hence, B. coagulans MTCC 5856 could be a potential agent in the management of diarrhea predominant IBS patients.
Sami Labs Ltd | Date: 2013-05-02
Dietary and nutritional supplements.